LeMaitre Vascular (NASDAQ:LMAT) Releases Q3 2025 Earnings Guidance

Key Points

• LeMaitre Vascular updated its Q3 2025 earnings guidance, forecasting earnings per share between $0.540 and $0.590 and revenue between $61.2 million and $63.2 million, both slightly above analysts' consensus estimates.
• The company's stock rose 1.5% to $85.60 on a trading volume of 340,794 shares, significantly higher than its average volume.
• CEO George W. LeMaitre sold 76,868 shares at an average price of $85.79, reducing his holdings by 4.10% while still retaining a significant stake in the company.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) updated its third quarter 2025 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 0.540-0.590 for the period, compared to the consensus estimate of 0.539. The company issued revenue guidance of $61.2 million-$63.2 million, compared to the consensus revenue estimate of $60.9 million. LeMaitre Vascular also updated its FY 2025 guidance to 2.230-2.370 EPS.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Barrington Research raised LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 price objective for the company in a research note on Wednesday. Cantor Fitzgerald upped their price objective on LeMaitre Vascular from $92.00 to $95.00 and gave the company a "neutral" rating in a research note on Wednesday. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $98.00.

LeMaitre Vascular Trading Down 2.1%

LMAT stock traded down $1.98 during trading on Friday, hitting $92.28. The company had a trading volume of 149,596 shares, compared to its average volume of 146,164. The business has a 50-day moving average of $83.35 and a 200-day moving average of $86.57. LeMaitre Vascular has a one year low of $71.42 and a one year high of $109.58. The stock has a market cap of $2.09 billion, a PE ratio of 44.80, a PEG ratio of 2.37 and a beta of 0.79. The company has a current ratio of 13.96, a quick ratio of 13.83 and a debt-to-equity ratio of 0.46.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 EPS for the quarter, beating the consensus estimate of $0.57 by $0.03. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%. The business had revenue of $63.15 million for the quarter, compared to analysts' expectations of $62.48 million. During the same period in the prior year, the business posted $0.52 earnings per share. The firm's revenue was up 15.0% on a year-over-year basis. Research analysts predict that LeMaitre Vascular will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 4th. Shareholders of record on Thursday, August 21st will be issued a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Thursday, August 21st. LeMaitre Vascular's dividend payout ratio is presently 38.83%.

Insider Activity

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 100,000 shares of the stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $93.51, for a total transaction of $9,351,000.00. Following the transaction, the chief executive officer directly owned 1,727,003 shares in the company, valued at approximately $161,492,050.53. This represents a 5.47% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In the last quarter, insiders sold 200,000 shares of company stock worth $17,907,857. 9.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On LeMaitre Vascular

A number of institutional investors and hedge funds have recently modified their holdings of LMAT. Geneos Wealth Management Inc. boosted its holdings in shares of LeMaitre Vascular by 250.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier's stock worth $47,000 after buying an additional 398 shares in the last quarter. Strs Ohio bought a new position in shares of LeMaitre Vascular during the 1st quarter worth approximately $168,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of LeMaitre Vascular by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,078 shares of the medical instruments supplier's stock worth $1,013,000 after buying an additional 539 shares in the last quarter. Jane Street Group LLC boosted its holdings in shares of LeMaitre Vascular by 738.7% during the 1st quarter. Jane Street Group LLC now owns 20,096 shares of the medical instruments supplier's stock worth $1,686,000 after buying an additional 17,700 shares in the last quarter. Finally, Intech Investment Management LLC boosted its holdings in shares of LeMaitre Vascular by 116.6% during the 1st quarter. Intech Investment Management LLC now owns 20,967 shares of the medical instruments supplier's stock worth $1,759,000 after buying an additional 11,288 shares in the last quarter. 84.64% of the stock is currently owned by institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.